RayzeBio (RayzeBio) DeferredTaxAndRevenue : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is RayzeBio DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

RayzeBio's current deferred tax and revenue for the quarter that ended in Sep. 2023 was $0.00 Mil.

RayzeBio DeferredTaxAndRevenue Historical Data

The historical data trend for RayzeBio's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RayzeBio DeferredTaxAndRevenue Chart

RayzeBio Annual Data

Trend

Dec20

Dec21

Dec22

DeferredTaxAndRevenue

RayzeBio Quarterly Data
	Dec20	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23
DeferredTaxAndRevenue	Get a 7-Day Free Trial			-	-	-	-	-

RayzeBio DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of RayzeBio's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.

RayzeBio (RayzeBio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RayzeBio inc (NAS:RYZB) » Definitions » DeferredTaxAndRevenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

5505 Morehouse Drive, Suite 300, San Diego, CA, USA, 92121

Website

https://www.rayzebio.com

RayzeBio inc is a company operating as vertically integrated radiopharmaceutical therapeutics company. The main objective of the company is defeating cancer with radiopharmaceutical medicines. It has a created a pipeline of multiple drug candidates, in therapeutic areas with significant market opportunities. They have a portfolio of potential RPT drug and development candidates that includes late-stage clinical programs, development programs and discovery programs.

Executives

Hauwermeiren Timothy Van	director	C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Maha Katabi	director	SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Viking Global Opportunities Drawdown Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Drawdown Portfolio Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Arvind Kush	officer: Chief Financial Officer	C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Wellington Biomedical Innovation Master Investors (cayman) Ii L.p.	10 percent owner	280 CONGRESS STREET, BOSTON MA 02210
Versant Ventures Vii Gp-gp, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Vii Gp, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kenneth Song	director, officer: President and Chief Executive	C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Susan Moran	officer: Chief Medical Officer	1232 RICHARDSON AVE, LOS ALTOS CA 94024
Venbio Global Strategic Gp Iii, L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Gp Iii, Ltd	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158
Venbio Global Strategic Fund Iii, L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Redmile Biopharma Investments Ii, L.p.	10 percent owner	LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129